He discusses the potential utility of KAT6 after presenting monotherapy data, and how it could be used in combination with palazestrant (a complete estrogen receptor antagonist). Plus, learning from the field in the estrogen receptor space, and an update on the progress of Olema's own pivotal tirals. The company's OPERA-1 monotherapy phase 3 of palazestrant is schedule to read in the fall.

Sean Bohen explains what he believes is the significance of the Roche announcement, and why he believes Olema's could potentially be a best in class oral SERD. Plus, a preview of data that will deliver sometime next year. Coverage brought to you by